Table_2_A T Cell Receptor Sequencing-Based Assay Identifies Cross-Reactive Recall CD8+ T Cell Clonotypes Against Autologous HIV-1 Epitope Variants.XLSX
HIV-1 positive elite controllers or suppressors control viral replication without antiretroviral therapy, likely via CTL-mediated elimination of infected cells, and therefore represent a model of an HIV-1 functional cure. Efforts to cure HIV-1 accordingly rely on the existence or generation of antigen-specific cytotoxic T lymphocytes (CTL) to eradicate infected cells upon reversal of latency. Detecting and quantifying these HIV-1-specific CTL responses will be crucial for developing vaccine and T cell-based immunotherapies. A recently developed assay, called MANAFEST, uses T cell receptor (TCR) Vβ sequencing of peptide-stimulated cultures followed by a bioinformatic pipeline to identify neoantigen-specific T cells in cancer patients. This assay is more sensitive than conventional immune assays and therefore has the possibility to identify HIV-1 antigenic targets that have not been previously explored for vaccine or T cell immunotherapeutic strategies. Here we show that a modified version of the MANAFEST assay, called ViraFEST, can identify memory CD8+ T cell responses against autologous HIV-1 Gag and Nef epitope variants in an elite suppressor. Nine TCR Vβ clonotypes were identified and 6 of these were cross-reactive for autologous variants or known escape variants. Our findings are a proof of principle that the ViraFEST assay can be used to detect and monitor these responses for downstream use in immunotherapeutic treatment approaches.
History
References
- https://doi.org//10.1038/nrmicro.2015.5
- https://doi.org//10.1097/COH.0b013e328345a328
- https://doi.org//10.1128/JVI.02165-06
- https://doi.org//10.1128/JVI.03380-13
- https://doi.org//10.1038/ni845
- https://doi.org//10.1016/j.immuni.2008.10.010
- https://doi.org//10.1073/pnas.0611244104
- https://doi.org//10.1182/blood-2005-12-4818
- https://doi.org//10.1038/487439a
- https://doi.org//10.3389/fimmu.2019.02485
- https://doi.org//10.3389/fimmu.2019.02310
- https://doi.org//10.3390/ijms19072000
- https://doi.org//10.1158/2326-6066.CIR-18-0129
- https://doi.org//10.1056/NEJMoa1716078
- https://doi.org//10.1186/s40425-019-0547-7
- https://doi.org//10.4049/jimmunol.1300373
- https://doi.org//10.1128/mBio.00473-16
- https://doi.org//10.1038/ni.2342
- https://doi.org//10.1016/S0167-5699(98)01299-7
- https://doi.org//10.4049/jimmunol.1001480
- https://doi.org//10.1371/journal.pone.0192098
- https://doi.org//10.1084/jem.20052319
- https://doi.org//10.1128/JVI.01958-08
- https://doi.org//10.1128/JVI.00548-10
- https://doi.org//10.1186/1742-4690-7-94
- https://doi.org//10.1158/1538-7445.AM2017-NG01
- https://doi.org//10.1186/1742-4690-10-152
- https://doi.org//10.1186/1742-4690-8-63
- https://doi.org//10.1038/nm992
- https://doi.org//10.1128/JVI.01369-07
- https://doi.org//10.1097/QAD.0b013e32833d8a38
- https://doi.org//10.1038/nature14053
- https://doi.org//10.1016/j.virol.2013.10.015
- https://doi.org//10.1128/JVI.01275-14
- https://doi.org//10.1182/blood-2009-04-217604
- https://doi.org//10.1073/pnas.050567397
- https://doi.org//10.1126/science.1195271
- https://doi.org//10.4049/jimmunol.174.12.7524
- https://doi.org//10.4049/jimmunol.179.5.3133
- https://doi.org//10.1128/JVI.00579-09
- https://doi.org//10.1086/528695
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity